Jamjoom Pharmaceuticals Factory Future Growth

Future criteria checks 3/6

Jamjoom Pharmaceuticals Factory is forecast to grow earnings and revenue by 11.2% and 12% per annum respectively. EPS is expected to grow by 12.2% per annum. Return on equity is forecast to be 24.2% in 3 years.

Key information

11.2%

Earnings growth rate

12.2%

EPS growth rate

Pharmaceuticals earnings growth	16.6%
Revenue growth rate	12.0%
Future return on equity	24.2%
Analyst coverage	Low
Last updated	06 Nov 2024

Recent future growth updates

Recent updates

Getting In Cheap On Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015) Is Unlikely

Apr 30

Earnings and Revenue Growth Forecasts

SASE:4015 - Analysts future estimates and past financials data (SAR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,718	487	424	440	4
12/31/2025	1,512	427	427	419	4
12/31/2024	1,359	390	246	267	1
9/30/2024	1,268	349	255	310	N/A
6/30/2024	1,233	332	201	264	N/A
3/31/2024	1,185	311	224	279	N/A
12/31/2023	1,101	292	250	296	N/A
9/30/2023	1,089	280	153	205	N/A
6/30/2023	1,034	248	158	206	N/A
3/31/2023	974	212	107	163	N/A
12/31/2022	917	171	142	229	N/A
9/30/2022	930	199	96	209	N/A
6/30/2022	903	212	117	258	N/A
3/31/2022	822	188	92	240	N/A
12/31/2021	736	171	102	229	N/A
12/31/2020	805	207	98	262	N/A
12/31/2019	732	157	135	204	N/A
12/31/2018	701	151	66	113	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4015's forecast earnings growth (11.2% per year) is below the savings rate (14.7%).

Earnings vs Market: 4015's earnings (11.2% per year) are forecast to grow faster than the SA market (6.5% per year).

High Growth Earnings: 4015's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4015's revenue (12% per year) is forecast to grow faster than the SA market (-0.2% per year).

High Growth Revenue: 4015's revenue (12% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4015's Return on Equity is forecast to be high in 3 years time (24.2%)

Jamjoom Pharmaceuticals Factory Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Price target increased by 11% to ر.س162

Consensus EPS estimates increase by 12%

Recent updates

Jamjoom Pharmaceuticals Factory Company to Report Q3, 2024 Results on Oct 27, 2024

Investor sentiment deteriorates as stock falls 16%

Now 24% overvalued after recent price rise

Second quarter 2024 earnings released: EPS: ر.س1.53 (vs ر.س1.23 in 2Q 2023)

Price target increased by 11% to ر.س162

Dividend of ر.س1.60 announced

Jamjoom Pharmaceuticals Factory Company Approves Cash Dividend for the Second Half of the Year 2023, Payable on June 13, 2024

Jamjoom Pharmaceuticals Factory Company, Annual General Meeting, Jun 04, 2024

Now 21% overvalued

Getting In Cheap On Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015) Is Unlikely

Consensus EPS estimates increase by 12%

Full year 2023 earnings: EPS exceeds analyst expectations

Jamjoom Pharmaceuticals Factory Company to Report Fiscal Year 2023 Final Results on Mar 25, 2024

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: ر.س1.10 (vs ر.س0.65 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ر.س1.23 (vs ر.س0.72 in 2Q 2022)

First quarter 2023 earnings released: EPS: ر.س1.21 (vs ر.س0.62 in 1Q 2022)

Investor sentiment improves as stock rises 30%

Less than half of directors are independent

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies